Ralliant (NYSE:RAL) Updates FY 2026 Earnings Guidance

Ralliant (NYSE:RAL) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share guidance of 2.760-2.900 for the period, compared to the consensus EPS estimate of 2.650. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion. Ralliant also updated its Q3 2026 guidance to 0.720-0.780 EPS.

Ralliant Stock Down 0.0%

NYSE RAL traded down $0.01 during trading on Thursday, reaching $66.96. 4,483,291 shares of the company’s stock were exchanged, compared to its average volume of 1,715,994. The company has a 50 day moving average price of $66.98 and a two-hundred day moving average price of $54.16. The stock has a market cap of $7.49 billion and a P/E ratio of -6.12. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.05 and a current ratio of 1.61.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The business had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities research analysts anticipate that Ralliant will post 2.64 EPS for the current fiscal year.

Ralliant Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is currently -1.83%.

Analyst Upgrades and Downgrades

RAL has been the subject of several recent analyst reports. Oppenheimer boosted their price objective on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. BMO Capital Markets started coverage on shares of Ralliant in a research report on Monday, July 20th. They issued a “market perform” rating and a $78.00 target price on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a research note on Monday, May 4th. Zacks Research raised shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Finally, Wall Street Zen downgraded shares of Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $73.00.

Ralliant News Summary

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Adjusted earnings and revenue beat expectations. Ralliant reported second-quarter adjusted EPS of $0.68, above the $0.63 consensus and up from $0.67 a year earlier. Revenue reached approximately $568 million, a 13% year-over-year increase and above analyst expectations. Ralliant Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management raised its 2026 guidance. Full-year adjusted EPS is now expected at $2.76-$2.90, above the $2.65 consensus, while revenue is projected at roughly $2.25-$2.30 billion, above prior market expectations. Ralliant Reports Second Quarter 2026 Results and Raises Full Year Guidance
• Positive Sentiment: Near-term expectations also improved. Third-quarter guidance calls for adjusted EPS of $0.72-$0.78 and revenue of $570 million-$590 million, both above consensus estimates of $0.68 and $556.4 million, respectively.
• Positive Sentiment: Cost savings could support future margins. Ralliant’s enterprise productivity program is expected to generate $50 million-$60 million in annualized savings by 2028, potentially improving profitability and cash generation. Ralliant Forecasts 2026 Revenue and Productivity Savings
• Neutral Sentiment: Trading was volatile. RAL was briefly halted under a limit-up/limit-down pause, indicating elevated intraday volatility around the earnings release rather than a change in the company’s fundamentals.
• Negative Sentiment: Reported results were less favorable than adjusted figures. GAAP EPS was $0.51 versus adjusted EPS of $0.68, and Ralliant continues to face substantial non-operating or special-item effects. Investors may therefore focus on the quality and sustainability of the adjusted earnings improvement.

Hedge Funds Weigh In On Ralliant

Institutional investors have recently modified their holdings of the business. Dodge & Cox boosted its stake in Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after purchasing an additional 1,434,376 shares during the period. Viking Global Investors LP purchased a new position in Ralliant during the 2nd quarter worth $257,200,000. State Street Corp acquired a new position in Ralliant in the second quarter valued at $213,096,000. Invesco Ltd. raised its holdings in shares of Ralliant by 4.9% in the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock valued at $206,674,000 after buying an additional 187,898 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its holdings in shares of Ralliant by 19.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,423,268 shares of the company’s stock valued at $174,279,000 after buying an additional 563,822 shares during the last quarter.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.